ENDOCYTE
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate recept... or positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
ENDOCYTE
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1996-01-01
Address:
West Lafayette, Indiana, United States
Country:
United States
Website Url:
http://www.endocyte.com
Total Employee:
51+
Status:
Active
Contact:
(765) 463-7175
Total Funding:
114.35 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail DMARC Vimeo AWS Global Accelerator Barracuda Networks Akamai DNS
Similar Organizations
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Oncotelic Therapeutics
Oncotelic is a biopharmaceutical company, develops anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Board_member
Board_observer
Board_member
2010-01-01
Current Employees Featured
Gwen Fyfe consultant @ Endocyte
consultant
2009-01-01
Founder
Stock Details
Investors List
MidCap Financial
MidCap Financial investment in Venture Round - Endocyte
Silicon Valley Bank
Silicon Valley Bank investment in Venture Round - Endocyte
Burrill & Company
Burrill & Company investment in Series C - Endocyte
Sanderling Ventures
Sanderling Ventures investment in Series C - Endocyte
Triathlon Medical Venture Partners
Triathlon Medical Venture Partners investment in Series C - Endocyte
Blue Chip Venture Company
Blue Chip Venture Company investment in Series C - Endocyte
Indiana University Health
Indiana University Health investment in Series C - Endocyte
American Bailey Ventures
American Bailey Ventures investment in Series C - Endocyte
American Bailey Ventures
American Bailey Ventures investment in Series C - Endocyte
CID Capital
CID Capital investment in Series C - Endocyte
Official Site Inspections
http://www.endocyte.com
- Host name: 104.18.5.189
- IP address: 104.18.5.189
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Endocyte"
Endocyte - Wikipedia
Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013 , the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis. See details»
Novartis announces planned acquisition of Endocyte to expand …
Oct 18, 2018 This offer values Endocyte's equity at USD 2.1 billion. Closing of the transaction is subject to customary closing conditions, including the approval of Endocyte's stockholders and …See details»
Endocyte - Crunchbase Company Profile & Funding
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The …See details»
Novartis successfully completes acquisition of Endocyte
Basel, December 21, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand …See details»
Endocyte 2025 Company Profile: Valuation, Investors, …
Endocyte General Information Description. Developer of receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases. The …See details»
Endocyte, Inc. Company Profile | Indianapolis, IN | Competitors ...
Company Description: Endocyte develops receptor-targeted therapeutics (or "smart drugs") that aim to take out bad cells without causing collateral damage. Receptor-targeted therapeutics …See details»
Novartis to acquire US cancer drug developer Endocyte …
Founded in 1996, Endocyte develops targeted therapeutics for cancer treatment. It is engaged in the development of 177Lu-PSMA-617, a potential radioligand therapy in Phase III development for the treatment of metastatic castration …See details»
Endocyte Company Profile - Office Locations, Competitors ... - Craft
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. It uses its proprietary drug conjugation …See details»
Endocyte - Funding, Financials, Valuation & Investors - Crunchbase
Endocyte is a biopharmaceutical company that develops receptor-targeted therapeutics to treat cancer and inflammatory diseases. New. Resources. Advanced Search. ... How much funding …See details»
Organization | Endocyte
Organization Overview. First Clinical Trial. 1999 NCT00003763. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Endocyte Active Ingredients. Drugs in Phase 3 …See details»
Endocyte - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 19, 2025 Endocyte is an acquired company based in West Lafayette (United States), founded in 1996 by Ron Ellis. It operates as a Develops targeted therapies for the treatment of …See details»
Endocyte - Products, Competitors, Financials, Employees, …
Endocyte. Frequently Asked Questions (FAQ) When was Endocyte founded? Endocyte was founded in 1996. Where is Endocyte's headquarters? Endocyte's headquarters is located at …See details»
Organization: Endocyte - Cbonds.com
Endocyte. Information about the issuer. News and credit ratings. . Tables with accounting and financial reporting.See details»
Endocyte starts renaissance by licensing ‘billion-dollar’ prostate ...
Oct 2, 2017 A few months ago, Endocyte was shedding R&D programs and staff, with questions being raised about its future. Now, it says its prospects have been resurrected by licensing a …See details»
Endocyte Management Team - CB Insights
Eight drugs stemming from his research are undergoing human clinical trials and seven companies (Endocyte Inc., OnTarget Laboratories Inc., Novosteo Inc., Erythrocure Inc., Umoja …See details»
Endocyte - Contacts, Employees, Board Members, Advisors & Alumni
Endocyte is a biopharmaceutical company that develops receptor-targeted therapeutics to treat cancer and inflammatory diseases. ... Solutions. Products. Resources. Pricing. Resources. …See details»
Endocyte becomes first Purdue startup to reach $1.5B in value
Oct 3, 2018 A turning point for Endocyte came in the fall of 2017 when the company obtained exclusive worldwide rights from a Germany company to develop and commercialize Lu-PSMA …See details»
Endocyte, Inc. (Endocyte, Inc.) - 药物管线_专利_临床试验_投融营 …
了解Endocyte, Inc. (Endocyte, Inc.)公司的药物管线，治疗领域，技术平台，以及它的35项临床试验, 51篇新闻和123篇文献，疾病领域:肿瘤，神经系统疾病，内分泌与代谢疾病，技术平台:多 …See details»
Endocyte Axing 40% of Workforce, Scales Back Development of …
Jun 2, 2017 Endocyte is also ending enrollment in a Phase I trial of a second cancer candidate, the prostate-specific membrane antigen targeted (PSMA-targeted) tubulysin prostate cancer …See details»
Endocyte Company Overview, Contact Details & Competitors
Dec 27, 2010 Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration …See details»